Tolerance induction for EGFR TKI hypersensitivity in lung cancer: Case report and review

Journal of Allergy and Clinical Immunology Global 2026 Open access

Read full text
Authors: Mizuha Haraguchi Hashiguchi, Takeya Adachi, Masato Asaoka, Tamaki Ito, Sachiko Kaburagi, Junko Kagyo, Utako Okata-Karigane, Chiaki Takahashi, Umi Tahara, Suzuyuki Yoneda, Katsunori Masaki, Koichi Fukunaga
DOI: 10.1016/j.jacig.2026.100706
Cited by: 1
References: 9

Abstract

This report highlights the successful use of oral desensitization to manage delayed-type hypersensitivity to afatinib, enabling continuation of treatment for epidermal growth factor receptor-mutated non-small cell lung cancer. In the absence of standardized protocols, it offers valuable insights for managing similar clinical challenges.

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Drug-Induced Adverse Reactions Cytokine Signaling Pathways and Interactions

Publication details

Journal / source
Journal of Allergy and Clinical Immunology Global
Publisher
Elsevier BV
Volume
5
Issue
4
Pages
100706–100706
Publication date
15 April 2026
Language
EN